Vancouver Island Technology Park
Unit 3204-4464 Markham Street
About ImmunoPreciseImmunoPrecise Antibodies provides its customers with custom antibody engineering and production services to support their research and development efforts.
Antibodies are naturally occurring proteins capable of binding to specific target molecules, or antigens. They have been used very widely in research assays, diagnostics, purification and therapeutics. The target market for the Company's antibody and peptide products includes organizations in the academic, biological, diagnostic and pharmaceutical fields. This is a large growing market that is expected to double in the next ten years.
CEO: Thomas D’Orazio
CTO: Robert Beecroft
CSO: Deanna Dryhurst
Please click here for ImmunoPrecise job opportunities.
Tweets by ImmunoPrecise
73 articles about ImmunoPrecise
Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2
IMMUNOPRECISE ANTIBODIES LTD. today announced that CEO Jennifer Bath will present to investors attending the LD 500 investor conference on Friday, September 4, 2020 at 1:00pm EST.
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is pleased to announce that additional characterization of a subset of fully human, therapeutic antibodies, already shown to have potent neutralizing activity, ar
IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology
ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is collaborating, pursuant to an agreement dated May 14, 2020 , in a multi-company effort with the laboratory of Dr. Fr
NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Responses
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration between University of Victoria ("UVic")-based laboratory of Dr. Alexandre Brolo , experts in the development of novel diagnostic too
IMMUNOPRECISE ANTIBODIES LTD., a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement with Janssen Research & Development, LLC, providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.
ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics
Entered into an LOI to form a Joint Venture as it partners in the continued development of antibody therapeutics to target T cell mediated anti-tumor activity, with AgonOx, a clinical-stage biopharma company. AgonOx specializes in identifying and developing immuno-oncology therapeutics.
Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery
2/9/2018ImmunoPrecise announces the appointment of Dr. Jennifer Bath, as the new President and CEO of the Company effective February 21, 2018.
ImmunoPrecise is pleased to announce the appointment of Dr. Robert Burke to the Company's Board of Directors.
The Transaction continues to realize on the Board's commitment to grow globally through strategic acquisitions.